To better understand derailed signaling in AML we performed extensive quantitative proteome and transcriptome analyses on a large cohort of primary AML patient samples and healthy CD34+ control hematopoietic stem/progenitor cells (HSPCs) and compared that with high-throughput LC-MC/MS (liquid chromatography-tandem mass spectrometry)-based targeted metabolomics analysis. This evidence concerns the gene CD34 and acute myeloid leukemia.